A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive
Interventions: DRUG: Zanidatamab|DRUG: Letrozole|DRUG: Tamoxifen
Sponsor: M.D. Anderson Cancer Center
Collaborators: Zymeworks BC Inc.